Infinity And AbbVie Collaborate To Develop & Commercialize Duvelisib In Oncology

(RTTNews) - Infinity Pharmaceuticals, Inc. (INFI) and AbbVie Inc. (ABBV) announced that they have entered into a global collaboration to develop and commercialize duvelisib (IPI-145), Infinity's oral inhibitor of phosphoinositide-3-kinase or PI3K-delta and PI3K-gamma, for the treatment of patients with cancer.

Duvelisib has shown clinical activity across a broad range of blood cancers, including indolent non-Hodgkin lymphoma or iNHL and chronic lymphocytic leukemia or CLL.

Infinity is conducting registration-focused trials evaluating the safety and efficacy of duvelisib, including DYNAMOTM, a Phase 2 study in patients with iNHL, and DUOTM, a Phase 3 study in patients with CLL.

As per the terms of the agreement, Infinity will receive an upfront payment of $275 million and is eligible to receive up to $530 million in additional payments for the achievement of development, regulatory and commercial milestones, including up to $405 million for the achievement of milestones through the first commercial sale of duvelisib.

In the U.S., the companies will jointly commercialize duvelisib and will share equally in any potential profits.

Outside the U.S., AbbVie will be responsible for conducting and funding of any commercialization of duvelisib, and Infinity is eligible to receive tiered royalties on net product sales, with percentages ranging from 23.5 percent to 30.5 percent.